MG-HI: The Myasthenia Gravis Health Index
MG-HI: The Myasthenia Gravis Health Index
- Type of Clinical Outcome Assessment (COA): Patient-reported outcome measure (PRO)
- Administration Mode: Self-administered
- Therapeutic Area: Myasthenia gravis
- Approximate Completion Time: <6 minutes
- Required Supervision: None
- Recall Period: Immediate point in time
Instrument Variations
- The Myasthenia Gravis Health Index Short Form (MG-HI-SF)
- MG-HI Short From Completion Time: Under 1 minute
Symptom Subscales
- Number of Independently Validated Symptom Subscales: 14
Mobility & Ambulation; Back, Chest, Neck & Abdominal Strength; Hand & Finger Function; Shoulder & Arm Function; Emotional Health; Social Health; Sleep & Daytime Sleepiness; Breathing Function; Activity Participation; Fatigue; Pain; Swallowing Function; Communication; Vision
Instrument Attributes
- The MG-HI is a patient-reported outcome (PRO) measure designed to assess symptoms and health-related quality-of-life from the perspective of patients with Myasthenia gravis.
- Designed and validated to fully satisfy regulatory and published FDA guidance for use in drug-labeling claims and measuring changes in how a patient feels and functions.
- The MG-HI is a fully valid, reliable, responsive, and disease-specific instrument capable of measuring changes in patient-reported health in patients with Myasthenia gravis.
- The instrument was developed using extensive patient input, including an analysis of 1,872 patient quotes and a large cross-sectional study involving 222 patients.
- The MG-HI is highly relevant to patients, has low patient burden, correlates with markers of disease severity, and demonstrates few floor and no ceiling effects.
- The MG-HI and its subscales demonstrated a high internal consistency (Cronbach α = 0.99 for the full instrument).
- English
Additional translations available upon request.
Pending
- “Initial Development of the Myasthenia Gravis-Health Index (MG-HI): Measuring the Most Prevalent and Impactful Symptoms Identified in Myasthenia Gravis”. C. Engebrecht, S. Rosero, S. Khosa, J. Weinstein, J. Seabury, A. Varma, C. Shupe, C. Irwin, A. Brocht, O. Carbunar, M. Benatar, C. Heatwole. The American Academy of Neurology 76th Annual Meeting; April 13-18, 2024; Denver, CO.
Instrument Scoring
All subscales are scored on a scale of 0 to 100 with 0 representing no disease burden and 100 representing the maximum level of disease burden. Symptom questions within each subscale are weighted based on participant-reported prevalence and average impact as identified through the cross-sectional study. Subscale scores are also weighted to generate a total MG-HI score (0-100) representing overall disease burden.